Clinical Phase i study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

Acta Oncologica

Volumn 50, Issue 3, 2011, Pages 441-447

  Ekman, Simon ^a,e   Frödin, Jan Erik ^b   Harmenberg, Johan ^c   Bergman, Antonina ^a   Hedlund, Åsa ^a   Dahg, Pia ^a   Alvfors, Carina ^d   Ståhl, Birgitta ^c   Bergström, Stefan ^a   Bergqvist, Michael ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXL 1717; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; NAVELBINE; PEMETREXED; PICROPDOPHYLLIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PERSONAL EXPERIENCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLID TUMOR; SQUAMOUS NON SMALL CELL LUNG CANCER; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR NECROSIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; TREATMENT OUTCOME;

EID: 79952672340     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.499370     Document Type: Article

References (13)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
2. Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 2009;10:923-36.
3. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions. Oncogene 2009;28:3009-21.
4. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64:236-42. (Pubitemid 38114104)
5. Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006;107:669-78. (Pubitemid 43076393)
6. Yin S, Girnita A, Stromberg T, Khan Z, Andersson S, Zheng H, et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 2010;12:19-27.
7. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, et al. Tumor cavitation: Impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009;27:404-10.
8. Hatzidaki D, Agelaki S, Mavroudis D, Vlachonikolis I, Alegakis A, Georgoulias V; Lung Cancer Group of the Hellenic Oncology Research Group. A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 2006;1:49-55. (Pubitemid 44336244)
9. Bedano PM, Hanna N. Salvage therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2006;6:582-7. (Pubitemid 47181409)
10. Karp DD, Paz-Ares L, Novello S, Haluska P, Garland L, Cardenal F, et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. ASCO Meeting Abstracts 2008;15 (Suppl):8015.
11. Kobayashi M, Okamoto K, Nakatani H, Okabayashi T, Namikawa T, Ichikawa K, et al. Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: Report of a case. Surg Today 2006;36:727-32. (Pubitemid 44127343)
12. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: Role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 2006;26:481-95. (Pubitemid 43515319)
13. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: A new paradigm for imaging. Oncologist 2008;13:8-13.